14 Ottobre 2026

therapy

A promising new weight loss and diabetes treatment helps burn fat while keeping muscle addome, sport, fitness

A promising new weight loss and diabetes treatment helps burn fat while keeping muscle

Redazione 31 Agosto 2026
Over the past five years, medications called GLP-1s have revolutionized the treatment of metabolic disorders like obesity,...
Per saperne di più Maggiori informazioni su A promising new weight loss and diabetes treatment helps burn fat while keeping muscle
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease anemia, sangue

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Redazione 19 Luglio 2026
The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy* (exagamglogene autotemcel) for patients...
Per saperne di più Maggiori informazioni su FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
Stem Cell Transplantation More Cost-Effective than Gene Therapy for Sickle Cell Disease tumore, prevenzione, genetica, terapia

Stem Cell Transplantation More Cost-Effective than Gene Therapy for Sickle Cell Disease

Redazione 3 Giugno 2026
Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults...
Per saperne di più Maggiori informazioni su Stem Cell Transplantation More Cost-Effective than Gene Therapy for Sickle Cell Disease
New data on spontaneous coronary artery dissection (SCAD), a common cause of heart attacks in younger women  fibrillazione atriale, cuore

New data on spontaneous coronary artery dissection (SCAD), a common cause of heart attacks in younger women 

Redazione 22 Febbraio 2026
New insights into spontaneous coronary artery dissection – a devastating cause of heart attacks in young, healthy...
Per saperne di più Maggiori informazioni su New data on spontaneous coronary artery dissection (SCAD), a common cause of heart attacks in younger women 
FDA approves PharmaMar’s Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-line Maintenance Therapy for Extensive-stage Small Cell Lung Cancer Schermata 2025-10-03 alle 18.43.19

FDA approves PharmaMar’s Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-line Maintenance Therapy for Extensive-stage Small Cell Lung Cancer

Redazione 3 Ottobre 2025
PharmaMar (MSE:PHM) has announced that the U.S Food and Drug Administration (FDA) has granted approval for Zepzelca® (lurbinectedin)...
Per saperne di più Maggiori informazioni su FDA approves PharmaMar’s Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-line Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
Increasing potassium levels improve outcomes in patients at high risk of ventricular arrhythmia #ESCCongress #ESC25

Increasing potassium levels improve outcomes in patients at high risk of ventricular arrhythmia #ESCCongress #ESC25

Redazione 1 Settembre 2025
Targeting high-normal potassium levels reduced the risk of arrhythmias, hospitalisation for heart failure or arrhythmia and death...
Per saperne di più Maggiori informazioni su Increasing potassium levels improve outcomes in patients at high risk of ventricular arrhythmia #ESCCongress #ESC25